|
|
Article: Sangretech Biomedical and Bostwick Laboratories Announce Amended License for Sangretech's Dendritic Cell Technology.
- Article from:
- Business Wire
- Article date:
- October 15, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Dendritic Cell Cryo-Immunotherapy to Be Studied as Potential Treatment for Advanced Prostate Cancer
SEATTLE -- Sangretech Biomedical LLC, a developer of dendritic cell therapies for cancer and infectious diseases, today announced it has executed an amended and restated license agreement with Bostwick Laboratories, Inc. providing Bostwick Scientific, the research division of Bostwick Laboratories, with exclusive rights to Sangretech's dendritic cell technology in certain territories.
Sangretech's technology will be used in the development and commercialization of VDC2008, Bostwick Scientific's clinical stage product candidate employing unloaded or ...